Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaginal lactobacilli
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Dalian Medical University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Vaginal lactobacilli refers to a live biotherapeutic product, typically formulated as a vaginal capsule, containing specific strains of *Lactobacillus* bacteria (such as *L. crispatus*, *L. gasseri*, or *L. jensenii*). These probiotics are intended to restore and maintain the natural vaginal microflora, which is predominantly composed of lactobacilli in healthy individuals. In clinical oncology, particularly for patients undergoing pelvic radiotherapy for gynecologic malignancies like cervical or endometrial cancer, these capsules are evaluated for their ability to prevent or mitigate radiotherapy-induced vaginal damage and dysbiosis. The bacteria function by producing lactic acid to maintain an acidic vaginal pH, generating hydrogen peroxide and bacteriocins to inhibit the overgrowth of pathogenic flora, and competing for adhesion sites on the vaginal epithelium, thereby reducing inflammation and promoting mucosal integrity.
- Brand names
- Duo Mei Ni
- Other names
- vaginal lactobacilli capsuleVaginal Lactobacillus CapsulesLactobacillus capsules阴道乳杆菌活菌胶囊
02
Targets
HCAR1 (Hydroxycarboxylic acid receptor 1)
Beyond the preview
Go deeper on vaginal lactobacilli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaginal lactobacilli.